The role of surgery in the management of epithelial ovarian cancer

Cancer Control

Volumn 18, Issue 1, 2011, Pages 22-30

  Ramirez, Ingrid ^a   Chon, Hye Sook ^b   Apte, Sachin M ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ABDOMINAL PAIN; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; INTERMETHOD COMPARISON; INTESTINE OBSTRUCTION; LAPAROSCOPIC SURGERY; LAPAROTOMY; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; OVARY CANCER; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PATIENT SAFETY; SECOND LOOK SURGERY; TREATMENT OUTCOME;

EID: 78651488929     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800104     Document Type: Article

References (81)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95(6):699-704.
3. Parazzini F, Valsecchi G, Bolis G, et al. Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival. Gynecol Oncol. 1999; 74(1):7-11.
4. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97(8):560-566.
5. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-1259.
6. Piver MS, Lele SB, Marchetti DL, et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol. 1988;6(6):983-989.
7. Young RC, Chabner BA, Hubbard SP, et al. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978;299(23):1261-1266.
8. Smith JP, Day TG Jr. Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol. 1979;135(7):984-993.
9. Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol. 1984;18(3):293-298.
10. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987;5(8):1157-1168.
11. Wharton JT, Edwards CL. Cytoreductive surgery for common epithelial tumours of the ovary. Clin Obstet Gynaecol. 1983;10(2):235-244.
12. Redman JR, Petroni GR, Saigo PE, et al. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol. 1986;4(4):515-523.
13. Heintz AP, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67(6):783-788.
14. Piver MS, Lele SB, Marchetti DL, et al. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol. 1988;6(11):1679-1684.
15. Potter ME, Partridge EE, Shingleton HM, et al. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits. Gynecol Oncol. 1989;32(3): 314-318.
16. Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47(2):203-209.
17. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.
18. Griffiths CT, Parker LM, Fuller AF Jr, et al. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979;63(2):235-240.
19. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974-979; discussion 979-980.
20. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69(2):103-108.
21. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559-564. Epub 2006 May 22.
22. Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621-3627.
23. Winter WE 3rd, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(1): 83-89. Epub 2007 Nov 19.
24. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-1244.
25. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001-1007.
26. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950-1955.
27. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
28. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27-32.
29. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993;11(1):166-172.
30. Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89(7):1532-1540.
31. Salani R, Axtell A, Gerardi M, et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2008;108(2):271-275.
32. Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384-389.
33. Dowdy SC, Mullany SA, Brandt KR, et al. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer. 2004;101(2):346-352.
34. Aletti GD, Gostout BS, Podratz KC, et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100(1):33-37.
35. Chi DS, Venkatraman ES, Masson V, et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol. 2000;77(2):227-231.
36. Chi DS, Zivanovic O, Palayekar MJ, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol. 2009;112(1):6-10.
37. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61(4):413-420.
38. Heintz AP, Van Oosterom AT, Trimbos JB, et al. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol. 1988;30(3):347-358.
39. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332(10):629-634.
40. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351(24):2489-2497.
41. Aletti GD, Dowdy SC, Podratz KC, et al. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1-677.
42. Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107(1):99-106.
43. Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71(3):431-436.
44. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol. 1999;72(1):93-99.
45. Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol. 2005;3:57.
46. Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res. 2006;32(1):99-106.
47. Giannopoulos T, Butler-Manuel S, Taylor A, et al. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 2006;27(1):25-28.
48. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105(1):211-217.
49. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer. 2001;91(12):2329-2334.
50. Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 1991;42(2):146-150.
51. Everett EN, French AE, Stone RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol. 2006;195(2):568-574; discussion 574-576.
52. Weinberg LE, Rodriguez G, Hurteau JA. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol. 2010;101(4):334-343.
53. Ghezzi F, Cromi A, Uccella S, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105(2):409-413.
54. Chi DS, Abu-Rustum NR, Sonoda Y, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005;192(5):1614-1619.
55. Park JY, Kim DY, Suh DS, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol. 2008;15(7):2012-2019.
56. Nezhat FR, Ezzati M, Chuang L, et al. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol. 2009;200(1):83.e1-6.
57. Tozzi R, Köhler C, Ferrara A, et al. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol. 2004;93(1): 199-203.
58. Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100(3): 455-461.
59. Childers JM, Lang J, Surwit EA, et al. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol. 1995;59(1):25-33.
60. Ramirez PT, Wolf JK, Levenback C. Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol. 2003;91(1):179-189.
61. Havrilesky LJ, Peterson BL, Dryden DK, et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol. 2003;102(2):243-251.
62. Canis M, Botchorishvili R, Manhes H, et al. Management of adnexal masses: role and risk of laparoscopy. Semin Surg Oncol. 2000;19(1):28-35.
63. Bakkum-Gamez JN, Richardson DL, Seamon LG, et al. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009;113(1):11-17.
64. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176-182.
65. Abu-Rustum NR, Barakat RR, Siegel PL, et al. Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy? Obstet Gynecol. 1996;88(4 Pt 1):549-553.
66. Casey AC, Farias-Eisner R, Pisani AL, et al. What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995? Gynecol Oncol. 1996;60(3):454-461.
67. Clough KB, Ladonne JM, Nos C, et al. Second look for ovarian cancer: laparoscopy or laparotomy? A prospective comparative study. Gynecol Oncol. 1999;72(3):411-417.
68. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519-2529.
69. Chu CS, Rubin SC. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep. 2001;3(1):11-18.
70. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95(2):273-280.
71. Güngör M, Ortaç F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97(1):74-79.
72. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005;92(6):1026-1032.
73. Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10(suppl 1):87-92.
74. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109(4):685-691.
75. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinumsensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933-1939.
76. Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007; 106(3):482-487.
77. Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104(3):686-690.
78. Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14(3):1136-1142.
79. Feuer DJ, Broadley KE, Shepherd JH, et al. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(4): CD002764.
80. Jong P, Sturgeon J, Jamieson CG. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg. 1995;38(5):454-457.
81. Pothuri B, Vaidya A, Aghajanian C, et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol. 2003;89(2):306-313.